Press Release

Tens of thousands of patients can get treatment in the coming years

NRG PALLAS and Curium have signed a long-term agreement to expand the current cooperation to include the production of lutetium-177 (Lu-177). The treatment isotope Lutetium will be added to the products already produced in Petten. This will enable Curium to supply about 70,000 doses of Lu-177 annually, which will help about 14,000 patients per year.

Bertholt Leeftink, CEO NRG PALLAS: “Curium and NRG PALLAS have been partners in the production of key medical isotopes since mid-nineties. The expansion of our cooperation with new irradiation services ensures a continuous supply of Lutetium for patients worldwide.”

Vinod Ramnandanlal, Commercial Director NRG PALLAS adds: “ NRG PALLAS already produces lutetium for other partners, and is now expanding this partnership with Curium. This fits with our aim to get more nuclear medicines available to patients faster. This will help meet the growing demand for Lu-177 around the world. Lutetium really makes a difference for patients with neuroendocrine tumors (NETs) and (metastatic) prostate cancer when it comes to life expectancy and quality of life. Beyond prostate cancer and NETs, Lu-177 is being used in (pre)clinical trials in many other indications, which will be beneficial for more patients in the long term.

NRG PALLAS is the operator of the HFR reactor that produces multiple isotopes for the diagnosis and treatment of various types of cancer and heart diseases. Curium's access to the capacity of the HFR allows the company to reliably meet the demand for Lu-177 products as well as meet the growing need.

NRG PALLAS' HFR reactor and Curium's Lu-177 production facility are both located at the Energy & Health Campus in Petten, which means that no time is lost in the production of lutetium (half-life) and the nuclear medicine can reach patients in Dutch and other hospitals as quickly as possible. To support its Lu-177 product platform, Curium is currently installing several Lu-177 production lines at its facilities in Petten.